Johnson CS - Search Results

1

Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer.

Trump DL, Potter DM, Muindi J, Brufsky A, Johnson CS. Trump DL, et al. Among authors: johnson cs. Cancer. 2006 May 15;106(10):2136-42. doi: 10.1002/cncr.21890. Cancer. 2006. PMID: 16598750 Free article. Clinical Trial.

2

Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancer.

Chadha MK, Tian L, Mashtare T, Payne V, Silliman C, Levine E, Wong M, Johnson C, Trump DL. Chadha MK, et al. Cancer. 2010 May 1;116(9):2132-9. doi: 10.1002/cncr.24973. Cancer. 2010. PMID: 20166215 Free article. Clinical Trial.

3

Calcitriol (1,25-dihydroxycholecalciferol) potentiates activity of mitoxantrone/dexamethasone in an androgen independent prostate cancer model.

Ahmed S, Johnson CS, Rueger RM, Trump DL. Ahmed S, et al. Among authors: johnson cs. J Urol. 2002 Aug;168(2):756-61. J Urol. 2002. PMID: 12131364

4

Vitamin D-related therapies in prostate cancer.

Johnson CS, Hershberger PA, Trump DL. Johnson CS, et al. Cancer Metastasis Rev. 2002;21(2):147-58. doi: 10.1023/a:1020836226594. Cancer Metastasis Rev. 2002. PMID: 12465754 Review.

5

Anti-tumor activity of calcitriol: pre-clinical and clinical studies.

Trump DL, Hershberger PA, Bernardi RJ, Ahmed S, Muindi J, Fakih M, Yu WD, Johnson CS. Trump DL, et al. Among authors: johnson cs. J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):519-26. doi: 10.1016/j.jsbmb.2004.03.068. J Steroid Biochem Mol Biol. 2004. PMID: 15225831 Review.

6

Pharmacokinetics of liquid calcitriol formulation in advanced solid tumor patients: comparison with caplet formulation.

Muindi JR, Potter DM, Peng Y, Johnson CS, Trump DL. Muindi JR, et al. Among authors: johnson cs. Cancer Chemother Pharmacol. 2005 Nov;56(5):492-6. doi: 10.1007/s00280-005-1015-2. Epub 2005 May 26. Cancer Chemother Pharmacol. 2005. PMID: 15918041 Clinical Trial.

7

Monocyte fructose 1,6-bisphosphatase and cytidine deaminase enzyme activities: potential pharmacodynamic measures of calcitriol effects in cancer patients.

Muindi JR, Peng Y, Wilson JW, Johnson CS, Branch RA, Trump DL. Muindi JR, et al. Among authors: johnson cs. Cancer Chemother Pharmacol. 2007 Jan;59(1):97-104. doi: 10.1007/s00280-006-0247-0. Epub 2006 May 6. Cancer Chemother Pharmacol. 2007. PMID: 16680461 Clinical Trial.

8

The antitumor efficacy of calcitriol: preclinical studies.

Johnson CS, Muindi JR, Hershberger PA, Trump DL. Johnson CS, et al. Anticancer Res. 2006 Jul-Aug;26(4A):2543-9. Anticancer Res. 2006. PMID: 16886662 Free article. Review.

9

Vitamin D compounds: clinical development as cancer therapy and prevention agents.

Trump DL, Muindi J, Fakih M, Yu WD, Johnson CS. Trump DL, et al. Among authors: johnson cs. Anticancer Res. 2006 Jul-Aug;26(4A):2551-6. Anticancer Res. 2006. PMID: 16886663 Free article.

10

Role of nongenomic activation of phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase 1/2 pathways in 1,25D3-mediated apoptosis in squamous cell carcinoma cells.

Ma Y, Yu WD, Kong RX, Trump DL, Johnson CS. Ma Y, et al. Among authors: johnson cs. Cancer Res. 2006 Aug 15;66(16):8131-8. doi: 10.1158/0008-5472.CAN-06-1333. Cancer Res. 2006. PMID: 16912191

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

565 results

Search Page

Filters